Abbott Laboratories

Abbott Laboratories (ABT) (Q3FY23) – Taming the cost curve with Libre sales

Highlights of the report

In Diabetes Care, Freestyle Libre sales surpassed $1.3bn in Q3FY23, marking a 25% growth on an organic basis. In Q3FY23, Libre achieved a milestone by becoming the first and only continuous glucose monitoring system to receive national reimbursement in France for all insulin-using individuals with diabetes. Abbott (ABT) distinguished itself through Libre, offering a fully-featured continuous glucose monitor at an affordable price.

CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.


CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).


Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional  Products, and Medical Devices.

Abbott Laboratories revenue decreased to $10.14bn in Q3FY23 from $10.41bn in Q3FY22. The gross profit margin was 49.7% for Q3FY23 compared to 50.7% in Q3FY22. It decreased to 50.1% for the 9MFY23 compared to 52.1% for the 9MFY22. The decrease in the Q3FY23 and 9MFY23 reflects the unfavorable effects of lower sales of COVID-19 tests, foreign exchange, and higher costs for various manufacturing inputs. 

Over the past 3 months Abbott Laboratories stock price decreased by (1%) from $103.75 on 24th Aug 2023 to $102.70 on 23rd Nov 2023. The stock price declined by (3%) in the past 1-year from $105.39 on 28th Nov 2022 to $102.70 on 2nd Nov 2023.



– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

Report details

Abbott Laboratories (ABT) (Q3FY23) – Taming the cost curve with Libre sales



Company Reports

Sector Reports